Skip to Main Content
Selected Highli..
++

The Newborn Infant chapter includes the new 2015 Neonatal Resuscitation Program (NRP) Guidelines for Neonatal Resuscitation.

++

The Child Abuse & Neglect chapter includes the use of nucleic acid amplification tests to diagnose sexually transmitted diseases in prepubertal children evaluated for sexual abuse.

++

The Immunization chapter includes new discussions about how HPV vaccination can prevent cancer, how a newer HPV vaccine protects against additional HPV types, and new discussion about how most parents in the United States choose to vaccinate their children (in 2013, < 1% of young children received no vaccines). Although parents' concerns about vaccines are on the rise, an increasing number of parents are choosing to delay or decline vaccination for their children.

++

The Poisoning chapter includes new recommendations for evaluation and treatment for common ingestions and exposures in the pediatric population, including pharmaceuticals, household products, and designer drugs.

++

The Skin chapter includes the use of propranolol for infantile hemangiomas.

++

The Eye chapter describes how instrument-based vision screening is a novel means of detecting vision-threatening amblyogenic risk factors in preverbal, preliterate, and developmentally delayed children, and is endorsed by the American Academy of Pediatrics.

++

The Oral Medicine & Dentistry chapter includes preventive dental treatment (fluoride varnish) by physicians for high-risk populations.

++

The Respiratory Tract & Mediastinum chapter introduces the new cystic fibrosis drug, Orkambi.

++

The Cardiovascular Diseases chapter includes three–dimensional echocardiography as a new diagnostic addition to noninvasive evaluation of congenital heart disease.

++

The Gastrointestinal Tract chapter identifies the life-threatening impact of button batteries as startling and significant health care problem.

++

The Liver & Pancreas chapter identifies two new oral therapies that are available for children with chronic hepatitis B: entecavir for children 3 years or older and tenofovir for children 12 years or older.

++

The Hematologic Disorders chapter notes that hydroxyurea therapy is now recommended for all children with sickle cell anemia or sickle β-thalassemia.

++

The Immunodeficiency chapter describes the use of genetic testing in the evaluation of children with immunodeficiency and states of immune dysregulation.

++

The Endocrine Disorders chapter includes the use of recombinant alkaline phosphatase (asfotase alfa) for the treatment of hypophosphatasia and how it has revolutionized therapy for this disorder.

++

The Genetics & Dysmorphology chapter includes information on microarray testing and whole exome sequencing.

++

The Antimicrobial Therapy chapter includes information on antimicrobial stewardship.

++

And many more!

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.